Viracta Therapeutics Ceases Operations Following Nasdaq Delisting

Viracta Therapeutics has officially terminated all business activities, marking a complete wind-down of the company. The firm’s website now confirms the full cessation of operations, concluding what was once a promising venture in the precision oncology sector.

The company’s board of directors enacted an immediate liquidation plan on February 5, 2025, resulting in the termination of all employees. This decisive action came directly on the heels of the company’s delisting Read more...